Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-05-24
2005-05-24
Smith, L. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S400000, C424S405000, C424S407000, C424S489000, C424S184100, C424S234100, C424S282100, C424S085100
Reexamination Certificate
active
06896888
ABSTRACT:
Disease cased by papilloma virus is treated by applying an effective amount ofMycobacteriumto the region of infection. Specifically, condylomata acuminata are caused by human papilloma virus infection. Despite numerous treatment modalities these patients often demonstrate recurrent disease. BCG therapy is used in primary treatment or in patients not responding to or recurrent after standard treatment. Six men with rapidly recurrent external and intraurethral condylomata acuminata underwent BCG therapy after initial laser treatment. External application and intraurethral instillation of BCG was performed six times in weekly intervals. Follow-up studies included examination and endoscopic inspection of the urethra and bladder. Three patients completed one course of BCG and had no relapse of condylomata acuminata. Two patients underwent a second course of BCG, of whom one relapsed. One patient relapsed after discontinued therapy due to penile edema. The annual recurrence rate decreased from 3.2 before the BCG therapy to 0.75 after BCG therapy (p<0.05, test of equality of 2 percentages). In addition, eight men underwent BCG therapy as primary therapy without initial laser treatment, following the same course of treatment, but employing BCG in a cream with salicylic acid to promote keratolysis. Six out of eight patients completely recovered. The BCG-induced immune response appears to reduce the recurrence rate in patients with condylomata acuminata.
REFERENCES:
patent: 2179858 (1987-03-01), None
Brandau et al., Urological Research (1997) vol. 25, No. 1, p. 94.*
Herr et al. (Journal of Urology vol. 141, pp. 22-29, 1989).*
Westenend et al., (BJU International (2001), 88,198-201).
Böhle Andreas
Jocham Dieter
Sim & McBurney
Smith L. F.
Zeman Robert A.
LandOfFree
Treatment of papilloma virus infection using a mycobacterium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of papilloma virus infection using a mycobacterium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of papilloma virus infection using a mycobacterium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3377257